The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the Pharmaceuticals, Biotechnology and Generics sectors of the overall health care industry, backed by a team of respected writers with many years of experience in the field.
Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
23 May 2013
Results of the INTERVAL study were published on line in The Lancet today (May 23) and for the
Latest Pharma Letter Articles
Alexza deal with Teva sets stage for Adasuve, say analysts
23 May 2013
USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered
Exec appointments at Biogen Idec and Halozyme; Succession plan for Forest Labs
23 May 2013
US biotech firm Biogen Idec (Nasdaq: BIIB) announced that Spyros Artavanis-Tsakonas, has been
Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
23 May 2013
Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck
Baxter and Halozyme's HyQvia approved in European Union
22 May 2013
USA-based Baxter International (NYSE: BAX) and Halozyme Therapeutics (Nasdaq: HALO) say that
Ranbaxy highlights its actions on improved business and quality assurance
23 May 2013
Indian drugmaker Ranbaxy Laboratories (BSE: 500359), whose US subsidiary was the subject of
Italy's pharma market slump set to continue, warns GlobalData
22 May 2013
The value of Italy's pharmaceutical market will continue to fall in the foreseeable future,
News From the Web
6 Biotechnology Stocks to Buy Now
22 May 2013
8 Biotechnology Stocks to Sell Now
22 May 2013
USP Offers Herbal Medicines Compendium
21 May 2013
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
